|
| Study | Study period | Total cases (E/C) | Age (E/C) | Male-female (E/C) | Accompanying diseases | Regimen | Duration (d) (E/C) | Previous treatment regimens | Adverse effects (E/C) | Outcomes | ITT eradication rates (%) (E/C) | PP eradication rates (%) (E/C) |
| Experimental group | Control group |
|
| Yao et al. [14] | 2017.11–2019.01 | 96/91 | 51.3 ± 9.7/50.5 ± 10.9 | 36-60/37-54 | Chronic gastritis; peptic ulcer | Control + Jinghua Weikang capsule 160 mg, tid | Esomeprazole 20 mg + amoxicillin 1.0 g/furazolidone 0.1 g + CLA 0.5 g + BPC 220 mg, bid | 14/14 | CLA triple therapy | 2/3 | ①②④ | NA | 83.90/71.30 |
| Chen et al. [15] | 2013.01–2017.12 | 50/50 | 36.8 ± 8.2/37.2 ± 7.8 | 23-27/20-30 | Chronic gastritis | Control + Jianpi Qingyou decoction 200 mL, bid | CBD 0.2 g + rabeprazole 10 mg + CLA 0.5 g + amoxicillin 1.0 g, bid | 14/14 | PPI triple therapy | NA | ①④ | NA | 93.80/73.50 |
| Liu [16] | 2015.03–2016.03 | 50/50 | 32.1 ± 16.5/35.6 ± 15.4 | 32-18/35-15 | Chronic gastritis; peptic ulcer | Control + Sijunzi formula 100 mL, bid+ | Bismuth quadruple therapy | 7/14 | Bismuth quadruple therapy, 14 d | NA | ① | 94.00/78.00 | NA |
| Zhang et al. [17] | 2015.01–2016.04 | 65/65 | 41.9 ± 11.0/44.9 ± 10.8 | 35-30/31-34 | NA | Berberine 0.3 g, tid + esomeprazole 20 mg + CBD 220 mg, bid; | Esomeprazole 20 mg + CBD 220 mg + tetracycline 750 mg + FZD 0.1 g bid | 14/14 | CLA + amoxicillin + PPI + bismuth, 14 d | 6/4 | ①②④ | 76.90/81.50 | 84.70/86.90 |
| Jiang et al. [18] | 2014.01–2015.10 | 91/91 | 49.6 ± 13.2/48.5 ± 11.6 | 43-48/51-40 | Peptic ulcer; chronic gastritis | Control + Qi’e decoction 1#, bid | Esomeprazole 20 mg + FZD 0.1 g, bid; LVFX 0.5 g, qd; Bacillus subtilis enterococcus capsule 0.5 g, tid | 14/14 | Standard triple therapy or bismuth quadruple therapy | 9/13 | ①②④ | 86.80/73.60 | 89.80/78.80 |
| Cheng et al. [19] | 2013.01–2014.12 | 90/89 | 48.0 ± 13.0/49.0 ± 12.0 | 37-53/36-53 | NA | Control + Jinghua Weikang capsules 240 mg, bid | BPC 220 mg + pantoprazole 40 mg + amoxicillin 1.0 g + FZD 0.1 g, bid | 10/10 | NA | 3/4 | ①② | 74.40/82.00 | 76.10/85.90 |
| Shang et al. [20] | 2011.01–2013.04 | 65/65 | 37.8 ± 3.3/37.3 ± 3.2 | 41–24/39–65 | Peptic ulcer; duodenal ulcer; gastric ulcer | Control + Chinese herbs 200 mL, bid | CLA 0.5 g + rabeprazole 20 mg + metronidazole 0.4 g, bid | NA | CLA + rabeprazole + amoxicillin | NA | ① | 86.15/69.23 | NA |
| Li [21] | 2011.01–2012.04 | 65/65 | 37.8 ± 3.3/37.3 ± 3.2 | 41-24/39-26 | Duodenal ulcer; peptic ulcer; gastric ulcer | Control + Chinese herbs 300 mL, bid | Amoxicillin 0.5 g + LVFX 0.2 g, bid; rabeprazole 20 mg, qd | NA | CLA + rabeprazole + metronidazole | NA | ①② | 86.15/69.23 | NA |
| Wang et al. [22] | 2014.01–2015.01 | 40/40 | 42.3 ± 12.2/44.8 ± 12.0 | 17-21/20-17 | NA | Chinese herbs 150 mL, bid for 28 days + amoxicillin 1 g bid + LVFX 0.5 g qd + rabeprazole 20 mg bid for 10 days; | Amoxicillin 1 g bid + LVFX 0.5 g qd + CBD 150 mg tid for 10 days; rabeprazole 20 mg bid for 18 days | 28/18 | Standard triple therapy | NA | ①④ | NA | 73.68/51.35 |
| Liu and Liu [23] | NA | 60/60 | 46.3 ± 11.4/46.8 ± 12.2 | 21-39/22-38 | NA | Control + Binlang Sixiao tablet 2.4 g, bid | Rabeprazole 10 mg + CBD 240 mg + amoxicillin 1.0 g + FZD 0.1 g, bid | 14/10 | NA | 7/13 | ①②③④ | 88.33/80.00 | 91.38/87.27 |
| Xia [24] | 2011.06–2013.06 | 28/28 | 39.6 ± 5.3/38.2 ± 4.7 | 20-8/19-9 | NA | Jinghua Weikang capsule 160 mg, tid for 4 weeks + moxifloxacin 0.4 g qd + amoxicillin 0.5 g + rabeprazole 10 mg bid | CLA 0.5 g + amoxicillin 0.5 g + rabeprazole 10 mg, bid | 14/14 | NA | 0/0 | ①②④ | 92.80/71.40 | NA |
| Pan et al. [25] | 2011.04–2013.04 | 49/48 | 43.1 ± 12.7/43.9 ± 14.4 | 28-21/25-23 | Chronic gastritis; peptic ulcer | Jiawei Zuojin pill + sequential therapy of esomeprazole 20 mg + amoxicillin 1.0 g + FZD 0.1 g, bid | Esomeprazole 20 mg + CBD 0.3 g + amoxicillin 1.0 g + FZD 0.1 g, bid | 10/10 | NA | 2/8 | ①②④ | 91.80/77.10 | 93.80/82.20 |
| Pan et al. [26] | 2011.01–2013.01 | 48/47 | 43.4 ± 12.1/44.3 ± 12.4 | 29-19/26-21 | Chronic gastritis; peptic ulcer | Zuojin pill + esomeprazole 20 mg + amoxicillin 1.0 g + FZD 0.1 g, bid | Esomeprazole 20 mg + CBD 0.3 g + amoxicillin 1.0 g + FZD 0.1 g, bid | 10/10 | NA | 2/8 | ①②④ | 81.30/80.90 | 84.80/86.40 |
| Ji et al. [27] | 2008.03–2010.11 | 58/40 | 42.3 ± 8.3/40.5 ± 10.1 | 37–21/26–14 | Chronic gastritis; gastric ulcer; duodenal ulcer | Control + Changzhong capsule 5#, tid | Omeprazole 20 mg + amoxicillin 1.0 g, bid + LVFX 0.5 g, qd | 20/7 | Standard triple therapy | 7/13 | ①②③ | 93.00/85.00 | 95.00/89.00 |
| Liu [28] | NA | 60/60 | 46.5 ± 11.7/46.3 ± 11.4 | 21-49/22-38 | NA | Control + Chinese herbs 200 mL, bid | Esomeprazole 20 mg + BPC 0.6 g + amoxicillin 1.0 g + FZD 0.1 g, bid | 14/7 | NA | 7/13 | ①②③④ | 88.33/80.00 | 91.38/87.27 |
| Tan et al. [29] | 2010.08–2012.04 | 33/29 | NA | NA | Gastric ulcer; duodenal ulcer; chronic gastritis | Jinghua Weikang capsule 160 mg, tid + rabeprazole 10 mg + LVFX 0.2 g + FZD 0.1 g, bid | Rabeprazole 10 mg + amoxicillin 1.0 g + moxifloxacin 0.4 g, bid + BPC 1.3 g, tid | 7/7 | Standard triple therapy | 3/2 | ①②④ | NA | 75.90/66.70 |
| Zhang et al. [30] | 2006.05–2007.11 | 32/30 | 42.5 ± 10.8/41.5 ± 11.3 | 17-15/14-16 | Duodenal, gastric and peptic ulcer; chronic gastritis | Jianwei Qingyou decoction + omeprazole 20 mg + amoxicillin 1.0 g + CLA 0.5 g, bid | Omeprazole 20 mg + amoxicillin 1.0 g + CLA 0.5 g + BPC 220 mg, bid | 7/7 | Standard triple therapy | NA | ① | 90.60/66.67 | 93.50/71.40 |
| Cha et al. [31] | 2005.02–2005.12 | 32/30 | 42.5 ± 10.8/41.5 ± 11.3 | 17-15/14-16 | Chronic gastritis; peptic ulcer | Jianwei granule 10 g, tid + omeprazole 20 mg + amoxicillin 1.0 g + CLA 0.5 g, bid | Omeprazole 20 mg + amoxicillin 1.0 g + CLA 0.5 g + BPC 220 mg, bid | 7/7 | Standard triple therapy | NA | ① | 90.60/66.67 | 93.50/71.40 |
|
